The first injection of ARCALYST® (rilonacept) should be performed under the supervision of a qualified healthcare professional.
Injection-site reactions: healthcare providers should explain to patients that almost half the patients in the clinical trials experienced a reaction at the injection site.
Infections: patients should be cautioned that ARCALYST has been associated with serious, life-threatening infections and not to initiate treatment with ARCALYST if they have a chronic or active infection.
Vaccinations: prior to initiation of therapy with ARCALYST, healthcare providers should review with adult and pediatric patients their vaccination history relative to current medical guidelines for vaccine use, including taking into account the potential of increased risk of infection during treatment with ARCALYST.
Additional assistance for patients taking ARCALYST, as well as their caregivers and healthcare providers, is available by calling Regeneron Pharmaceuticals Medical Information at 1-877-REGN-777 (1-877-734-6777).
View the dosing instructions for adult patients and pediatric patients aged 12 to 17 years.Review the Information
ARCALYST® (rilonacept), an interleukin-1 blocker, is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children age 12 and over. It has not been studied in patients with Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
Please see the full Prescribing Information for ARCALYST.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.
IL-1 blockade may interfere with immune response to infections. Serious, life-threatening infections have been reported in patients taking ARCALYST. ARCALYST should be discontinued if a patient develops a serious infection. Taking ARCALYST with TNF inhibitors is not recommended because this may increase the risk of serious infections.